PET-determination of robalzotan (NAD-299) induced 5-HT(1A) receptor occupancy in the monkey brain

Neuropsychopharmacology

Volumn 22, Issue 4, 2000, Pages 422-429

  Farde, Lars ^a   Andrée, Bengt ^a   Ginovart, Nathalie ^a   Halldin, Christer ^a   Thorberg, Seth Olov ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

5 HT(1A) receptors; carbonyl 11CJWAY 100635; Antidepressive and Anxiolytic drugs; Monkey brain; NAD 299; Positron Emission Tomography; Robalzotan

Indexed keywords

N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RADIOLIGAND; ROBALZOTAN; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG RECEPTOR BINDING; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY;

ANIMALS; BENZOPYRANS; BRAIN; KINETICS; MACACA; RADIOLIGAND ASSAY; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN ANTAGONISTS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033955702     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00125-6     Document Type: Article

References (44)

1. Andrée B., Thorberg S.-O., Halldin C., Farde L. Pindolol binding to 5-HT1A receptors in the human brain confirmed with Positron Emission Tomography. Psychopharmacology. 144:1999;303-305.
2. Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry. 51:1994;248-251.
3. Baldwin D., Rudge S. The role of serotonin in depression and anxiety. Intl Clin Psychopharmacol. 9:1995;41-45.
4. Berendsen H.H. Interactions between 5-hydroxy-tryptamine receptor subtypes. Is a disturbed receptor balance contributing to the symptomatology of depression in humans? Pharmacol Therap. 66:1995;17-37.
5. Berman R.M., Darnell A.M., Miller H.L., Anand A., Charney D.S. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression. A double-blind, placebo-controlled trial Am J Psychiatry. 154:1997;37-43.
6. Blier P., Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clinical Psychopharmacol. 15:1995;217-222.
7. Burnet P.W., Eastwood S.L., Harrison P.K. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology. 15:1996;442-455.
8. 2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. J Cereb Blood Flow Metab. 9:1989;696-708.
9. Farde L., Gionvart N., Ito H., Lundkvist C., Pike V.W., McCarron J.A., Halldin C. PET-characterization of [carbonyl-11C]WAY-100635 binding to 5-HT1A receptors in the primate brain. Psychopharmacology. 133:1997;196-202.
10. 2 dopamine receptor binding in the living human brain by PET. Science. 231:1986;258-261.
11. Farde L., Ito H., Swahn C.-G., Pike V.W., Halldin C. Quantitative analysis of [carbonyl-11C]WAY-100635 binding to central HT1A receptors in man. J Nucl Med. 39:1998;1965-1971.
12. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry. 49:1992;538-544.
13. Gagner Milchert I., Gabrielson J., Lindhe J., Terelius Y. In vitro- in vivo extrapolation of robalzotan metabolic parameters. An interspecies comparison Eur Neuropsychopharmacol. 8:1998;184.
14. Gurevich E.V., Joyce J.N. Alterations in the cortical serotonergic system in schizophrenia. A postmortem study Biol Psychiatry. 42:1997;529-545.
15. Hall H., Lundkvist C., Halldin C., Farde L., Pike V.W., McCarron J.A., Fletcher A., Cliffe I.A., Barf T., Wilkstrom H., Sedvall G. Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H[WAY-100625 and [11C]way-100635. Brain Res. 745:1997;96-108.
16. Hashimoto T., Kitamura N., Kajimoto Y., Shirai Y., Shirakawa O., Mita T., Nishino N., Tanaka C. Differential changes in serotonin 5-HT1A and 5-HT2 receptor binding in patients with chronic schizophrenia. Psychopharmacology. 112:1993;S35-S39.
17. Hashimoto T., Nishino N., Nakai H., Tanaka C. Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci. 48:1991;355-363.
18. Hjorth S., Carlsson A. Is pindolol a mixed agonist-antagonist at central serotonin (5-HT) receptors? Eur J Pharmacol. 129:1986;131-138.
19. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev. 46:1994;157-203.
20. Ito H., Hietala J., Blomqvist G., Halldin C., Farde L. Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding. J Cereb Blood Flow Metab. 18:1998;941-950.
21. Johansson L., Sohn D., Thornberg S.O., Jackson D.M., Kelder D., Larsson L.G., Renyi L., Ross S.B., Wallsten C., Eriksson H., Hu P.S., Jerning E., Mohell N., Westlind-Danielson A. The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299. J Pharmacol Exp Therap. 283:1997;216-225.
22. Joyce J.N., Shane A., Lexow N., Winokur A., Casanova M.F., Kleinman J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology. 8:1993;315-336.
23. 11C]NNC756 as radioligands for PET-determination of central D1-dopamine receptors. Psychopharmacology. 113:1993;149-156.
24. Karlsson P., Farde L., Halldin C., Sedvall G., Ynddal L., Sloth-Nielsen M. Oral administration of NNC 756& - a placebo controlled PET study of D1-dopamine receptor occupancy and pharmacodynamics in man. Psychopharmacology. 119:1995;1-8. a.
25. Karlsson P., Farde L., Halldin C., Swahn C., Sedvall G. Evaluation of [11C]SCH39166 as D1-dopamine receptor ligand for central D1 dopamine receptor binding and occupancy in man. Psychopharmacology. 121:1995;309-316. b.
26. Larsson L.G., Stenfors C., Ross S.B. Differential regional antagonism of 8-OH-DPAT-induced decrease in serotonin synthesis by two 5-HT1A receptor antagonists. Eur J Pharmacol. 346:1998;209-215.
27. Marazziti D., Marracci S., Palego L., Rotondo A., Mazzanti C., Nardi I., Ladinsky H., Giraldo E., Borsini F., Cassano G.B. Localization and gene expression of serotonin 1A (5HT1A). Receptors in human brain postmortem Brain Res. 658:1994;55-59.
28. McAskill R., Mir S., Taylor D. Pindolol augmentation of antidepressant therapy. Br J Psychiatry. 173:1998;203-208. [published erratum appears in Br J Psychiatry 173:443, 1998].
29. Moreno F.A., Gelenberg A.J., Bachar K., Delgado P.L. Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry. 58:1997;437-439.
30. Oksenberg D., Peroutka S.J. Antagonism of 5-hydroxytryptamine1A (5-HT1A). receptor-mediated modulation of adenylate cyclase activity by pindolol and propranolol isomers Biochem Pharmacol. 37:1988;3429-3433.
31. Pazos A., Probst A., Palacios J.M. Serotonin receptors in the human brain. III. Autoradiographic mapping of serotonin-. 1(receptors. Neuroscience 21):1987;97-122.
32. Perez V., Gilaberte I., Faries D., Alvarez E., Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 349:1997;1594-1597.
33. Perez V., Soler J., Puigdemont D., Alvarez E., Artigas F. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorms Afectius. Arch Gen Psychiatry. 56:1999;375-379.
34. Peroutka S.J., Howell T.A. The molecular evolution of G protein-coupled receptors. Focus on 5-hydroxytryptamine receptors Neuropharmacology. 33:1994;319-324.
35. Pike V.W., McCarron J.A., Lammertsma A.A., Osman S., Hume S.P., Sargent P.A., Bench C.J., Cliffe I.A., Fletcher A., Grasby P.M. Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11C]WAY-100635. Eur J Pharmacol. 301:1996;R5-R7.
36. Romero L., Celada P., Artigas F. Reduction of in vivo striatal 5-hydroxytryptamine release by 8-OH-DPAT after inactivation of Gi/G(o) proteins in dorsal raphe nucleus. Eur J Pharmacol. 265:1994;103-106.
37. Sandell J., Halldin C., Chou Y.-W., Thornberg S.-O., Sohn D., Werner T., Farde L. Metabolic studies measured by HPLC in monkey plasma of the new 5-HT1A radioligand [C-11]NAD-299. J Labell Comp Radiopharm. 42(Suppl 1):1999;675-677. a.
38. Sandell J., Halldin C., Hall H., Thorberg S.-O., Werner T., Sohn D., Sedvall G., Farde L. Radiosynthesis of autoradiographic evaluation of [11C]NAD-299, a radioligand for visualization of the 5-HT1A receptor. Nucl Med Biol. 26:1999;159-164. b.
39. Saxena P.R. Serotonin receptors. Subtypes, functional responses and therapeutic relevance Pharmacol Therap. 66:1995;339-368.
40. Stenfors C., Werner T., Ross S.B. In vivo labelling of the mouse brain 5-hydroxytryptamine 1A receptor with the novel selective antagonist 3H-NAD-299. Naunyn-Schmiedebergs Arch Pharmacol. 357:1998;500-507.
41. Sumiyoshi T., Stockmeier C.A., Overholser J.C., Dilley G.E., Meltzer H.Y. Serotonin 1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res. 708:1996;209-214.
42. Tome M.B., Isaac M.T., Harte R., Holland C. Paroxetin and pindolol. A randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency Intl Clin Psychopharmacol. 12:1997;81-89.
43. Wienhard K., Dahlbom M., Eriksson L., Michel C., Bruckbauer T., Pietrzyk U., Heiss W. The ecat exact hr. Performance of a new high resolution position scanner J Comp Ass Tomogr. 18:1994;110-118.
44. Zanardi R., Artigas F., Franchini L., Sforzini L., Gasperini M., Smeraldi E., Perez J. How long should pindolol be associated with paroxetine to improve the antidepressant response? J Clin Psychopharmacol. 17:1997;446-450.